Abpro Holdings, INC 8-K filings

Abpro Holdings, formed through a business combination with Atlantic Coastal Acquisition Corp. II, is set to begin trading on Nasdaq under the tickers ABP and ABPWW.

Atlantic Coastal Acquisition Corp. II filed a Form 8-K to correct a typographical error in previous filings regarding the estimated per share redemption price, updating it from $11.28 to $11.34.

Atlantic Coastal Acquisition Corp. II has entered into a forward purchase agreement with YA II PN, LTD. for up to 500,000 shares, linked to its business combination with Abpro Corporation.

Atlantic Coastal Acquisition Corp. II stockholders have approved the proposed business combination with Abpro Corporation at a special meeting held on November 7, 2024.

Atlantic Coastal Acquisition Corp. II entered into a non-redemption agreement with Sandia Investment Management LP, ensuring the reversal of potential share redemptions ahead of its business combination with Abpro Corporation.

Atlantic Coastal Acquisition Corp. II has entered into a Standby Equity Purchase Agreement with YA II PN, Ltd., providing up to $5 million in pre-paid advances and a potential $50 million in future equity purchases.

Atlantic Coastal Acquisition Corp. II received a delisting notice from Nasdaq for failing to meet listing requirements, but plans to appeal and expects to regain compliance upon closing its business combination with Abpro Corporation.

Atlantic Coastal Acquisition Corp. II plans to merge with Abpro Corporation, a biotechnology company focused on antibody therapies, in a deal valued at approximately $500 million.

Atlantic Coastal Acquisition Corp. II has successfully extended its deadline to complete a business combination to October 19, 2024, with a possible further extension to November 19, 2024, following a shareholder vote.

Atlantic Coastal Acquisition Corp. II has amended its business combination agreement with Abpro Corporation, modifying the payment of unpaid expenses to its sponsor.

Atlantic Coastal Acquisition Corp. II has entered into subscription agreements with Abpro Bio and Celltrion to raise $11.2 million in a private investment in public equity (PIPE) offering, concurrent with their planned business combination with Abpro Corporation.

Atlantic Coastal Acquisition Corp. II has extended the deadline to complete a business combination from August 19, 2024, to September 19, 2024.

Atlantic Coastal Acquisition Corp. II received a notice from Nasdaq for failing to maintain the minimum required number of shareholders, potentially leading to delisting.

Atlantic Coastal Acquisition Corp. II has extended its deadline to complete a business combination from July 19, 2024, to August 19, 2024.

Atlantic Coastal Acquisition Corp. II has extended the deadline to complete a business combination from June 19, 2024, to July 19, 2024.

Atlantic Coastal Acquisition Corp. II received a notice from Nasdaq for non-compliance with listing standards due to a delay in filing its quarterly report.

Atlantic Coastal Acquisition Corp. II has entered into an agreement with its sponsor for up to $600,000 in interest-free advances to support working capital and the proposed merger with Abpro Corporation.

Atlantic Coastal Acquisition Corp. II has extended the deadline to complete a business combination from May 19, 2024, to June 19, 2024.

Atlantic Coastal Acquisition Corp. II received a delisting notice from Nasdaq for failing to meet minimum public float and market value requirements, but expects to resolve this through its planned merger with Abpro Corporation.

Atlantic Coastal Acquisition Corp. II has entered into a subscription agreement for a capital contribution of up to $360,000 to support its working capital needs and facilitate its upcoming business combination.

Atlantic Coastal Acquisition Corp. II (ACAB) has filed an amendment to its Registration Statement for a proposed business combination with Abpro Corporation, a biotechnology company focused on antibody therapies.

Atlantic Coastal Acquisition Corp. II has extended its deadline to complete a business combination from March 19, 2024, to April 19, 2024.

Atlantic Coastal Acquisition Corp. II has filed a registration statement on Form S-4 with the SEC in connection with its proposed business combination with Abpro Corporation.

Atlantic Coastal Acquisition Corp. II has amended its Sponsor Letter Agreement, adjusting share allocations among key parties in preparation for its merger with Abpro Corporation.